ACOG Committee Opinion No. 773: The Use of Antimüllerian Hormone in Women Not Seeking Fertility Care.
Level 5 - mechanism / opinion, no new human data
Professional clinical committee opinion and narrative guidance without primary empirical data or systematic review metrics.
PubMed 30913198 · doi:10.1097/AOG.0000000000003162
What was done
This American College of Obstetricians and Gynecologists (ACOG) Committee Opinion evaluated the clinical utility of serum antimüllerian hormone (AMH) testing for fertility counseling and reproductive outcome prediction in reproductive-aged women not seeking fertility care or diagnosed with infertility.
What was found
The abstract provides no numerical data or statistical metrics. It concludes that although AMH declines with reproductive age and has utility for ovarian reserve assessment in infertile populations, a single AMH measurement in presumed-fertile women does not reliably predict time to pregnancy. Routine AMH screening is not recommended for predicting pregnancy loss, and insufficient evidence exists to support its use for predicting time to menopause, diagnosing polycystic ovary syndrome, or forecasting menses resumption after gonadotoxic therapy.
Why it matters
This guideline clarifies clinical boundaries against the commercial and off-label use of AMH as a general measure of natural fertility potential in women without established fertility issues.
Limits
The abstract contains no primary data, sample sizes, or quantitative risk estimates. The recommendations are constrained by a reported lack of high-quality prospective studies evaluating AMH in low-infertility-prevalence populations.
Cited by
- supports The American College of Obstetricians and Gynecologists (ACOG) recommends that women should not have AMH testing unless they have infertility.